Skip to main content
Caplight Logo









Apeiron Therapeutics

Apeiron Therapeutics

Private
Burlingame, CaliforniaHealthcare & Life Scienceshttps://www.apeiron-bio.com/

Last Round

Series A

Mar 29, 2022

Total Funding Raised

$44.5M

Company Overview

Apeiron Therapeutics is a biotechnology company that develops biomarker-driven cancer therapeutics using a structure-based, AI-driven drug design platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

precision oncologyAI drug discoverysmall molecule therapyPRMT5 inhibitorMTAP deletionsynthetic lethalitytechbiostructure-based drug designclinical stage biotechbiomarker-driven therapybrain-penetrant drugsolid tumor treatmentdrug licensingoral cancer therapyKIF18A inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apeiron Therapeutics Comparables

Compare Apeiron Therapeutics with similar companies based on industry and business-model similarity.

Apeiron Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Recursion Pharmaceuticals
81%
Tango Therapeutics
80%
Bristol Myers Squibb
78%

Apeiron Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 29, 2022
SeedJun 11, 2019

Key People

Founding team and executive leadership

Mingxi Li

Chief Executive Officer

Executive Team

Apeiron Therapeutics Investors

Notable investors and investment history

Apeiron Therapeutics investors
InvestorRounds
Viva BioInnovatorSeries A
GT Healthcare Capital PartnersSeed
Panacea Venture HealthcareSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Monthly visitors grew 80% MoM, reaching 1.2K.

  • May 1, 2025

    Monthly visitors grew 298% MoM, from 377 to 1.5K.

Apeiron Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Apeiron Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Apeiron Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range16
Year Founded2019
Last FundingMar 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?